MA-EVERBRIDGE
25.1.2021 13:32:08 CET | Business Wire | Press release
Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced COVID-19 Shield™: Vaccine Distribution , an extension to its CEM platform offering risk insights, logistics awareness and vaccine appointment management to support the full spectrum of organizations that develop, manufacture, transport, distribute, regulate, and administer the coronavirus vaccine. The offering also provides governments with a single, unified platform to expedite vaccine coordination, communication and distribution for all residents, including vulnerable populations with special needs. Representing significant adoption for its vaccine distribution software, Everbridge announced the deployment of its CEM Platform to power the digital vaccination distribution system for a variety of municipalities and organizations, including the entire state population of West Virginia , and the County of Sarasota, Florida , among others.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005258/en/
“We have partnered with Everbridge,” said Governor Jim Justice of West Virginia in a recent press conference for state residents. “Everbridge helps states notify their citizens when there’s a fire, a flood, or a hurricane, but now they are going to help us coordinate vaccines as we can get them from the federal government. We will be the first state to turn on this new vaccine scheduling system. Everbridge helped us stand this up in one week’s time.”
In the U.S., healthcare experts have stated : “at a pace of one million doses a day, the virus wouldn’t be contained until sometime in 2022.” A recent survey also reveals that 6 in 10 Americans do not know when or where to get the vaccine. In addition, the logistics of moving this type of vaccine across the country in a short period of time creates a substantial challenge , especially given the cruciality of cold chain monitoring .
Added Gov. Justice, “This system [provides residents] the ability to put your information in directly and helps us coordinate when vaccines are available to notify you when and where to come to get your vaccine. You will get a message back after you’ve registered to confirm that you are in the system and we will send you updates regularly. The system sends emails, texts, and phone calls. Whatever way you want us to notify you about your availability, [Everbridge] will let you pick up on just that.”
“During a pandemic, efficient, expeditious and equitable distribution and administration of [the] approved vaccine is critical,” as stated by the U.S. Centers for Disease Control and Prevention (CDC) in their recent guidelines . Everbridge’s new COVID-19 Shield™: Vaccine Distribution software offers federal, state and local governments as well as businesses and healthcare systems new capabilities to: better manage vaccine supply chains amidst other concurrent critical events, analyze risk of virus spread, avoid operational disruptions, and ensure the smooth rollout of vaccines to employees and citizens with easy-to-deploy software integrations.
For governments, Everbridge enables state, city and county leaders to rapidly coordinate communication across the population, automate appointment signup and monitor registrations, track vaccine availability, ensure doses are shipped to proper facilities to avoid spoilage, and enable citizen scheduling to avoid long waits and call center challenges.
Demonstrating the extreme pent up demand and need for technology to assist in the communications, scheduling and distribution of the vaccine, the County of Sarasota, Florida leveraged Everbridge’s vaccine distribution software to enable 50,000 residents to sign up for the COVID-19 vaccine in the first hour of launch, which has been reported as ‘a giant leap forward.’ “We are utilizing Everbridge to coordinate the vaccine distribution in our community,” said Rich Collins, Director of Sarasota County Emergency Services. “The system aids in tracking and prioritizing this process, which allows us to serve our vulnerable populations and frontline workers.”
“We applaud Governor Justice and the state of West Virginia for their leadership in applying best practices to help keep their citizens safer and accurately informed through effective vaccine distribution. Solving this public health crisis faster will unlock the ability for governments to fully re-open economies for the betterment of all states, people and businesses,” said David Meredith, CEO of Everbridge. “The expansion of the Everbridge critical event management software platform to include vaccine distribution creates new ways for government, healthcare and all types of businesses to automate logistics, maintain vital communications and keep people safe during this crucial rollout.”
With Everbridge’s COVID-19 Shield™: Vaccine Distribution, enterprise customers gain capabilities to: coordinate the number of employees who have been vaccinated, manage population density and access to office buildings based on vaccination status, and receive timely alerts when employees report signs of illness so they can quickly respond to safeguard staff and visitors.
“Garnet Healthcare is providing mobile COVID testing and care across Vermont, New York, and Massachusetts,” said Ryan Ferris, CEO & Co-founder at Garnet Healthcare , which provides patient logistics, care coordination, and clinical diagnostics to healthcare institutions, corporate clients, and governmental agencies across New England. “Everbridge’s CEM Platform provides situational awareness of threats to our clinical logistics which could inhibit or delay these critical services. In addition, the platform provides coordination support to help us manage the testing process and follow-up with patients supporting our end-to-end clinical services.”
The new Everbridge COVID-19 Shield™: Vaccine Distribution software solution includes the following features among the suite’s broader CEM capabilities:
- Enhanced COVID-19 Risk Feed showcasing vital real-time information, including the incidence of new virus strains and vaccine related intelligence;
- Crisis Management Module to follow, log and audit the transport, handling, and/or administration of the vaccine;
- Vaccine Distribution Logistics Service to provide situational awareness to better manage vaccine supply chains;
- Customized Employee Surveys to help confirm whether employees have received the vaccine;
- Appointment Management Tool to help manage the scheduling, tracking and communications of vaccine administration; and
- Out-of-Box Workflows in Smart Orchestration to help improve distribution management, such as vaccine appointment follow-ups.
“Everbridge helps to bridge the gap between the public sector and the private sector,” said Mark Aprigliano, Senior Director, Public Safety at Jackson Health System . “Their CEM Platform provides situational awareness of threats to the supply chain for the vaccine which could inhibit or delay distribution. It also provides a common operating picture to all of the stakeholders in that supply chain, providing visibility and a coordinated effort from manufacturing to point of vaccination.”
To learn more best practices for distribution and management of the vaccine rollout, join Everbridge and Dr. Scott Gottlieb, former U.S. Food & Drug Administration Commissioner for a discussion entitled “The End of the Pandemic: Successful Vaccine Distribution ” on Wednesday, January 27, 2021 at 11:30 a.m. ET.
About Everbridge
Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,400 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 20 cities around the globe. For more information visit www.everbridge.com
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005258/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
